These are the posts from the How we think section that have been tagged with Biomarkers.
To see all tags used in our posts, click here.
|25th October 2018
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians navigating this complex landscape.
|19th September 2016
Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through what this means for pharma strategists and their product lines.
|12th June 2015
Blue Latitude Health sent two of our consultants to Chicago to attend ASCO 15, a key annual meeting for oncology specialists that brings over 30,000 delegates together to talk about innovations and progress in the field. David takes us through the highlights of the event and his take on the exciting developments that came out of the conference.
|12th March 2015
The modern pharmaceutical market can be saturated with competing products, from bio-similars, to same in-class, to alternative MoA treatments. Standing out from the crowd can be tough; innovative and patient serving methods of differentiation are hard to come by.
Consultant Mark Assenti talks through the use of biomarkers in pharma marketing and where it's headed in 2015.
|17th February 2014
Customer data is collected and used by almost every marketing department globally to better target audiences, so is it now time to take the next step, and add DNA to the pharma marketing mix? Mark Assenti explores the ethical and scientific issues behind genetic marketing.